Search research articles
Contact Us
Filters
Showing results (1-10 of 15) with videos related to
Page
of 2
Sort By:
Advances in Pharmacological Sciences
|
February 25, 2012
An Overview of the CNS-Pharmacodynamic Profiles of Nonselective and Selective GABA Agonists
Xia Chen, Sanne de Haas, Marieke de Kam, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 13, 2013
Markers of response for the antiangiogenic agent bevacizumab
Diether Lambrechts, Heinz-Josef Lenz, Sanne de Haas, et al.
Journal of Clinical Sleep Medicine : JCSM : Official Publication of the American Academy of Sleep Medicine
|
September 7, 2007
Exploratory polysomnographic evaluation of pregabalin on sleep disturbance in patients with epilepsy
Sanne de Haas, Andreas Otte, Al de Weerd, et al.
Epilepsia
|
October 29, 2004
Subjective sleep disturbance in patients with partial epilepsy: a questionnaire-based study on prevalence and impact on quality of life
Al de Weerd, Sanne de Haas, Andreas Otte, et al.
Angiogenesis
|
February 22, 2014
Genetic markers of bevacizumab-induced hypertension
Diether Lambrechts, Matthieu Moisse, Paul Delmar, et al.
Angiogenesis
|
July 12, 2014
Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy
Sanne de Haas, Paul Delmar, Aruna T Bansal, et al.
American Journal of Respiratory and Critical Care Medicine
|
December 16, 2006
Effect of an NK1/NK2 receptor antagonist on airway responses and inflammation to allergen in asthma
Johan D Boot, Sanne de Haas, Svetlana Tarasevych, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 9, 2012
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial
Eric Van Cutsem, Sanne de Haas, Yoon-Koo Kang, et al.
The Lancet. Oncology
|
May 22, 2012
VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials
Diether Lambrechts, Bart Claes, Paul Delmar, et al.
Cancer
|
July 19, 2019
Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNE
Edith A Perez, Carlos Barrios, Wolfgang Eiermann, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 15) with videos related to
Sort By:
Page
of 2
Advances in Pharmacological Sciences
|
February 25, 2012
An Overview of the CNS-Pharmacodynamic Profiles of Nonselective and Selective GABA Agonists
Xia Chen, Sanne de Haas, Marieke de Kam, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 13, 2013
Markers of response for the antiangiogenic agent bevacizumab
Diether Lambrechts, Heinz-Josef Lenz, Sanne de Haas, et al.
Journal of Clinical Sleep Medicine : JCSM : Official Publication of the American Academy of Sleep Medicine
|
September 7, 2007
Exploratory polysomnographic evaluation of pregabalin on sleep disturbance in patients with epilepsy
Sanne de Haas, Andreas Otte, Al de Weerd, et al.
Epilepsia
|
October 29, 2004
Subjective sleep disturbance in patients with partial epilepsy: a questionnaire-based study on prevalence and impact on quality of life
Al de Weerd, Sanne de Haas, Andreas Otte, et al.
Angiogenesis
|
February 22, 2014
Genetic markers of bevacizumab-induced hypertension
Diether Lambrechts, Matthieu Moisse, Paul Delmar, et al.
Angiogenesis
|
July 12, 2014
Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy
Sanne de Haas, Paul Delmar, Aruna T Bansal, et al.
American Journal of Respiratory and Critical Care Medicine
|
December 16, 2006
Effect of an NK1/NK2 receptor antagonist on airway responses and inflammation to allergen in asthma
Johan D Boot, Sanne de Haas, Svetlana Tarasevych, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 9, 2012
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial
Eric Van Cutsem, Sanne de Haas, Yoon-Koo Kang, et al.
The Lancet. Oncology
|
May 22, 2012
VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials
Diether Lambrechts, Bart Claes, Paul Delmar, et al.
Cancer
|
July 19, 2019
Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNE
Edith A Perez, Carlos Barrios, Wolfgang Eiermann, et al.
Page
of 2